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RESEARCH LETTER
Interleukin-6 Signaling Effects on Ischemic 
Stroke and Other Cardiovascular Outcomes
A Mendelian Randomization Study
Marios K. Georgakis , MD, PhD; Rainer Malik, PhD; Dipender Gill , BMBCh, PhD; Nora Franceschini , MD, MPH;  
Cathie L. M. Sudlow, DPhil; INVENT Consortium*; CHARGE Inflammation Working Group*; Martin Dichgans , MD
Downregulation of IL-6 (interleukin-6) signaling has been proposed as a strategy for lowering cardio-vascular risk. Secondary analyses from CANTOS 
(Canakinumab Anti-Inflammatory Thrombosis Outcomes 
Study) demonstrated that the therapeutic benefit of 
IL-1β (interleukin-1β) inhibition on cardiovascular pre-
vention was associated with the reduction of IL-6 levels 
and that the residual cardiovascular risk was proportional 
to post-treatment IL-6 levels.1 Moreover, Mendelian ran-
domization (MR) analyses showed variation in IL-6R 
(IL-6 receptor) gene (IL6R) to be associated with risk of 
coronary artery disease.2 Thus, directly interfering with 
IL-6 signaling might lower cardiovascular risk beyond 
IL-1β inhibition. Whether such an approach would be 
effective for ischemic stroke and other cardiovascular 
outcomes (aortic aneurysm, carotid plaque, peripheral 
artery disease, atrial fibrillation, heart failure, and throm-
botic phenotypes) remains unknown.
Here, we identified genetic proxies for IL-6R-me-
diated downregulation of IL-6 signaling as variants 
within a region 300 kB 5′ to 300 kB 3′ to IL6R that 
were associated with lower CRP (C-reactive protein) 
levels. CRP is a well-established downstream molecule 
of IL-6 signaling and a clinically useful biomarker for 
assessing residual inflammatory cardiovascular risk. 
Variants were derived from a genome-wide associa-
tion study of 204 402 European individuals (P<5×10−8; 
clumped at r2<0.1). We identified 7 single- nucleotide 
polymorphisms (SNPs) that served as instruments for 
downregulated IL-6 signaling (3 situated within IL6R). 
In conditional Genome-wide Complex Trait Analysis - 
conditional and joint (GCTA-CoJo) analyses3 adjusting 
for the lead SNP (rs2228145), P values for all SNPs 
were <0.05 (for SNPs within IL6R<0.0083-Bonferroni-
corrected threshold) indicating independent effects 
on CRP levels. F statistics ranged from 81 to 764. To 
validate these instruments, we explored associations 
of genetically downregulated IL-6 signaling with cir-
culating upstream regulators (IL-6, soluble IL-6R) and 
downstream molecules (fibrinogen) of the IL-6 signaling 
pathway. In accordance with trials testing tocilizumab 
versus placebo,2 genetically downregulated IL-6 signal-
ing was associated with higher circulating IL-6 and solu-
ble IL-6R levels and lower fibrinogen levels (Figure [A]).
Two-sample inverse-variance weighted MR analy-
ses showed genetically downregulated IL-6 signaling 
to be associated with lower risks of ischemic stroke 
(MEGASTROKE: 34 217 cases and 404 630 controls) 
and coronary artery disease (Coronary Artery Disease 
Genome-wide Replication and Meta-analysis plus Coro-
nary Artery Disease Genetics [CARDIoGRAMplusC4D]: 
60 801 cases and 123 504 controls; Figure [B and C]). 
We further found associations with lower risks of large 
artery and small vessel stroke, but not cardioembolic 
stroke (Figure [D]). Alternative MR approaches (weighted 
median, contamination-mixture, MR-PRESSO) and sen-
sitivity analyses restricted to the variants within IL6R all 
showed consistent association estimates.
MR analyses revealed no significant associations 
between genetically determined CRP and ischemic 
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stroke or its subtypes independently of whether we used 
all variants associated with CRP (187 SNPs) or SNPs at 
the CRP locus (24 SNPs). Furthermore, in permutations 
of MR analyses4 randomly selecting 7 of the 187 SNPs 
associated with CRP, the effects of the 7 SNPs selected 
as instruments for downregulated IL-6 signaling on isch-
emic stroke and its subtypes were consistently located 
below the lowest fifth percentile of the respective dis-
tributions (Figure [E]). Thus, the observed effects were 
independent of the effects of CRP.
Finally, we expanded the analyses to other cardiovas-
cular outcomes in the UK Biobank (321 406 individuals) 
and phenotype-specific genome-wide association study 
data sets. Genetically downregulated IL-6 signaling was 
significantly associated with lower risks of myocardial 
infarction and aortic aneurysm. We further found sug-
gestive associations (P<0.05) with atrial fibrillation and 
carotid plaque (Figure [F]). Again, these associations 
were independent of CRP levels.
Our results strongly support the candidacy of IL-6 sig-
naling as a target for vascular prevention over and beyond 
previous data. CANTOS targeted IL-1β rather than IL-6R 
thus providing only indirect evidence for a benefit of inter-
fering with IL-6 signaling.1 Also, CANTOS explored a 
combined end point rather than individual cardiovascular 
outcomes. Regarding stroke, there was a 7% reduction 
in incident events in the IL-1β arm, which did not reach 
statistical significance, and data on stroke subtypes were 
not available.5 Our MR results provide evidence for direc-
tionally consistent effects of IL-6 signaling on ischemic 
stroke and other cardiovascular outcomes and offer a 
solid basis for future trials exploring the benefit of phar-
macological IL-6R inhibition for these phenotypes.
Our results are in broad agreement with a recent 
MR study using the same data sources but a differ-
ent approach to explore the effects of IL-6 signaling 
on cardiovascular outcomes.6 While that study used 
plasma levels of soluble IL-6R to proxy the effects 
of IL-6 signaling, we used CRP levels, which might 
explain some discrepancies in the results. We did 
not select variants based on their effects on IL-6 or 
soluble IL-6R because they are upstream regulators 
of IL-6 signaling and variants increasing their levels 
could also upregulate the pathway. Still, IL-6 signal-
ing is complex with a classical and a trans-signaling 
component and disentangling the 2 subpathways 
goes beyond the limitations of MR.
In conclusion, this study provides evidence for a causal 
effect of IL-6 signaling on ischemic stroke, particularly 
large artery and small vessel stroke, as well as a range of 
cardiovascular phenotypes. IL-6R blockade might repre-
sent a valid therapeutic target for lowering cardiovascular 
risk and should thus be further investigated in clinical trials.
All data related to the effects of these variants on 
specific outcomes are publicly available as summary sta-
tistics from the respective sources. Data for outcomes 
derived from the UK Biobank are available after submis-
sion of a research proposal. All the data are also available 
from the corresponding author upon reasonable request. 
All individual studies had obtained ethical approval by the 
appropriate institutional review committees, as described 
in the original publications.
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Figure. Genetic proxies for downregulated IL-6 (interleukin-6) signaling and their effects on ischemic stroke and other 
cardiovascular outcomes in Mendelian randomization analyses (MR).
A, Effects of pharmacological inhibition of IL-6R (tocilizumab 8 mg/kg versus placebo for 8–24 weeks) and of genetic downregulation of IL-6 
signaling on IL-6 (Ntrials=1446 and Ngenetics=8293), sIL-6R (soluble IL-6 receptor; Ntrials=1465 and Ngenetics=3301), and fibrinogen (Fg) levels 
(Ntrials=1108 and Ngenetics=120 246). B, Genetically downregulated IL-6 signaling in association with ischemic stroke and coronary artery disease 
as derived from inverse-variance weighted (IVW) analyses using the full set of 7 single-nucleotide polymorphisms (SNPs) as instruments or 
the 3 SNPs located within the IL6R gene. C, SNP-specific effects of the associations with ischemic stroke. D, Genetically downregulated 
IL-6 signaling and ischemic stroke subtypes. E, Distributions of the effects of 7 randomly selected CRP (C-reactive protein)-decreasing SNPs 
on risk of ischemic stroke and the position of the effect of the IL-6 signaling downregulating SNPs included in our analyses. F, Genetically 
downregulated IL-6 signaling with other cardiovascular outcomes. Effect sizes for genetically downregulated IL-6 signaling are scaled to the 
CRP-decreasing effects of tocilizumab (8 mg/kg). Statistical significance thresholds are set at P<0.05/3=0.017 for the 3 ischemic stroke 
subtypes, and at P<0.05/9=0.0055 for the 9 cardiovascular outcomes. Associations showing P values <0.05 are considered suggestive. SMD 
indicates standardized mean difference.
